We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Performance Compared for Three Ebola Rapid Diagnostic Tests

By LabMedica International staff writers
Posted on 01 Oct 2020
Print article
Image: DPP Ebola Antigen System is a 15 minute rapid test for detection of Ebola Virus Specific Antigen (Photo courtesy of Chembio Diagnostic Systems).
Image: DPP Ebola Antigen System is a 15 minute rapid test for detection of Ebola Virus Specific Antigen (Photo courtesy of Chembio Diagnostic Systems).
Ebola is a rare but deadly virus that causes fever, body aches, and diarrhea, and sometimes bleeding inside and outside the body. As the virus spreads through the body, it damages the immune system and organs. Ultimately, it causes levels of blood-clotting cells to drop.

Diagnosing Ebola virus disease (EVD) shortly after infection can be difficult. Early symptoms of EVD such as fever, headache, and weakness are not specific to Ebola virus infection and often are seen in patients with other more common diseases, like malaria and typhoid fever. Polymerase chain reaction (PCR) is one of the most commonly used diagnostic methods because of its ability to detect low levels of Ebola virus.

An international team of scientists collaborating with Columbia University (New York, NY, USA) evaluated the three rapid diagnostic Tests (RDTs) in 109 Ebola-positive and 96 Ebola-negative stored serum samples collected during the outbreak in Guinea in 2014/15, and tested by real-time polymerase chain reaction (RT-PCR). Sensitivity, specificity, and overall percent agreement were calculated for each RDT using RT-PCR as a reference standard, stratified by Ct value ranges.

All tests evaluated in the study used the Dual Path Platform (DPP; Chembio Diagnostic Systems, Medford, NY, USA) technology, which consists of an immunochromatographic test cartridge and a small, battery-operated reflectance reader. The DPP Fever Panel Antigen System (the “Fever Panel Test”) is a multiplex assay detecting Plasmodium falciparum (HRP2), pan-Plasmodium (pLDH), and protein antigens specific for Lassa, Pan-Ebola (Zaire, Sudan, Bundibugyo), Marburg, Dengue, Chikungunya, and Zika Viruses. The DPP Ebola Antigen System (the “Ebola Test”) tests for Ebola Zaire antigen, and the DPP Ebola-Malaria Antigen duplex system (the “Ebola-Malaria Test”) detects Ebola Zaire antigen, Plasmodium falciparum (HRP2), and pan-Plasmodium (pLDH). All tests are qualitative and detect the VP40 antigen, which is specific to Ebola.

The investigators reported that all tests performed with high accuracy on samples with low Ct value (high viral load). The Fever Panel test performed with the highest accuracy, with a sensitivity of 89.9% and specificity of 90.6%. The Ebola and Ebola-Malaria tests performed comparably to each other: sensitivity was 77.1% and 78% respectively, and specificity was 91.7% for the Ebola test and 95.8% for the Ebola-Malaria test.

The authors concluded that their study had evaluated the accuracy of three novel rapid diagnostic tests for Ebola. The tests may have significant public health relevance, particularly the Fever Panel test, which detects seven pathogens including Ebola. Given limitations to the study resulting from uncertain sample quality, further evaluation is warranted. All tests performed with highest accuracy on samples with low Ct value (high viral load), and the data presented suggests that these RDTs may be useful for point-of-care diagnosis of cases in the context of an outbreak. The study was published on September 15, 2020 in the journal BMC Infectious Diseases.




Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.